Psychiatrist at University of Basel, SÄPT member, Head researcher for the Swiss MAPS program
After 2014 it became possible to treat patients in Switzerland in an out-patient setting with case-by-case licenses for MDMA, LSD and psilocybin. These licenses are issued by the the Swiss Federal Office of Public Health based on the Swiss Narcotics Act which allows for a restricted medical use of scheduled psychotropic drugs.
After initially using these substances in a one-to-one setting, a group model was developed which includes up to 12 patients and 3 therapists within a 3-day format. This presentation describes this substance-assisted group psychotherapy model, the requirements for therapists and patients, methodological and therapeutic challenges, patient characteristics, outcomes and observations made from 2014 - 2020.
Medical School University of Basel, Switzerland. Specialist degree in Psychiatry and Psychotherapy 1988. Psychotherapeutic training in Guided Affective Imagery Therapy, Systemic Couple and Family Therapy and in Psycholytic Therapy.
In private practice 1988-2020. Special interest in altered states of consciousness and psychedelic substances for more than 35 years. Member of the Swiss Medical Association for Psycholytic Therapy (SAePT). PI of Swiss phase II MDMA/PTSD-study. 2014-2020 licensed substance-assisted psychotherapy with MDMA and LSD in private practice.